4/18
09:11 am
mbrx
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML) [Yahoo! Finance]
Medium
Report
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML) [Yahoo! Finance]
4/18
08:30 am
mbrx
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
Medium
Report
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
4/13
02:04 am
mbrx
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
4/12
01:25 pm
mbrx
Moleculin Biotech, Inc. (NASDAQ: MBRX) had its "buy" rating re-affirmed by analysts at Roth Mkm. They now have a $40.00 price target on the stock.
Low
Report
Moleculin Biotech, Inc. (NASDAQ: MBRX) had its "buy" rating re-affirmed by analysts at Roth Mkm. They now have a $40.00 price target on the stock.
4/10
08:43 am
mbrx
Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties [Yahoo! Finance]
Medium
Report
Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties [Yahoo! Finance]
4/10
08:30 am
mbrx
Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
Medium
Report
Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
4/5
02:08 am
mbrx
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
3/28
10:45 am
mbrx
Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference
Medium
Report
Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference
4/18
08:30 am
mbrx
Form 8-K Moleculin Biotech, Inc. For: Apr 18
Low
Report
Form 8-K Moleculin Biotech, Inc. For: Apr 18
4/10
08:30 am
mbrx
Form 8-K Moleculin Biotech, Inc. For: Apr 10
Low
Report
Form 8-K Moleculin Biotech, Inc. For: Apr 10
4/8
05:15 pm
mbrx
Form 8-K Moleculin Biotech, Inc. For: Apr 08
Medium
Report
Form 8-K Moleculin Biotech, Inc. For: Apr 08
3/27
09:06 am
mbrx
Form 8-K Moleculin Biotech, Inc. For: Mar 27
Medium
Report
Form 8-K Moleculin Biotech, Inc. For: Mar 27
3/25
03:04 pm
mbrx
Form 8-K Moleculin Biotech, Inc. For: Mar 25
Low
Report
Form 8-K Moleculin Biotech, Inc. For: Mar 25
3/25
07:30 am
mbrx
Form 8-K Moleculin Biotech, Inc. For: Mar 25
High
Report
Form 8-K Moleculin Biotech, Inc. For: Mar 25
3/22
04:08 pm
mbrx
Form 8-K Moleculin Biotech, Inc. For: Mar 22
Medium
Report
Form 8-K Moleculin Biotech, Inc. For: Mar 22
3/22
04:06 pm
mbrx
Form 10-K Moleculin Biotech, Inc. For: Dec 31
High
Report
Form 10-K Moleculin Biotech, Inc. For: Dec 31
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd lot
Avg. bid-ask spread
Avg. bid-ask size
Shares at ask/bid
Off exchange
Main News & Impact Reports
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Register